THE VALUE OF EARLY INDICATIONS OF BREAST ABNORMALITIES WITH NON‐INVASIVE SURFACESCREENING OF THE BREAST WITH HIGH RESOLUTION MEDICAL INFRARED THERMOGRAPHY  

Jeanne Stryker, M.D., Board Certified Radiologist and Anti‐aging & Regenerative Medicine, Carol Chandler , DOM.

Early Redefined:

We must reconsider the definition of “early” as it applies to breast abnormalities. Medical Infrared
Thermography provides the practitioner the tool to detect surface vascular physiological abnormalities of
the breast to reveal potential microscopic pathology deep in the tissue. On average, the first eight (8) years of
a tumor’s growth pattern remains in the microscopic stage, even at four years with 65,536 cells. The currently
accepted definition of “early” detection by screening with mammography begins when it reaches the clinically
detectable size of approximately 15mm, slightly more than 1/2 inch. A tumor of this size includes close to 1 billion cancer cells.

Why use Thermography for Breast Screening?

Active Cancer Cells Can Double in Number Every 90 Days
90 days 2 cells
1 year 16 cells
2 years 256 cells
3 years 4,096 cells
4 years 65,536 cells
5 years 1,048,576 cells
6 years 16,777,216 cells
7 years 268,435,456 cells < 1 cm
8 years 4,294,967,296 cells > 2 cm (doubled 32 times)

Preventing breast cancer through early warning and preventative treatment protocols has the expectancy to
reduce the incidence of late‐stage recognition of breast disease. Comprehensive and readily available commercial thermography imaging facilities are the best delivery model to foster better patient healthcare through early detection of suspicious physiological activity.

BREAST CANCER IS A PROGRESSIVE DISEASE:

As breast cancer is a progressive disease, the point at which intervention takes place becomes criticallyimportant. To make a difference practitioners must start to place an emphasis on detecting the vascular signs of disease in its earliest formative stages, years before current clinical detection.

Proponents of mammography suggest a decrease in mortality rate due to clinical screenings, which is misleading. The best approach is the use of preventative protocols for early detection as a complement to mammography screening strategies. Only then can we reasonably expect mortality rates to decline significantly.

The prerequisite for effective pre‐clinical surface screening is a specialized breast care center operated by licensed, highly trained and motivated professionals working as a team. The goal is to maximize the benefits of non‐invasive thermographic screening while minimizing the risk and expense to the patient.

Highly developed thermal imaging technology with high degree of specificity is required to minimize the number of healthy individuals subjected to unnecessary invasive procedures. Differentiating benign from malignant is a highly difficult task ‐ even for radiology. As a complimentary imaging tool, medical infrared provides new and vital information to assist the practitioner. The appropriate use of all available tools facilitates improved options and outcomes for the patient.

THERE ARE MANY SUBTYPES OF BREAST CANCER:

The many subtypes of breast cancer have different physiological indications, growth patterns and growth
rates. It’s an oversimplification to expect that such a heterogeneous disease can be detected using only one
modality; consequently comprehensive breast screening requires access to all modern imaging modalities with
emphasis on prevention to give the patient responsible treatment options.

CONCLUSION:

Experience has taught mankind that the only way to effectively control any disease is to prevent
it in the first place. The possibility of controlling breast disease through clinical late‐stage detection and
treatment is not a reality as seen by the ever increasing number of cases. Alternatively, the woman and her
health care provider need to recognize the importance of the vascular physiological changes observed by
thermographic screening to reveal a pre‐cancerous microscopic entity. In addition, medical professionals need to be educated and informed of the benefits of pre‐clinical detection as the best means of prevention of
diseases like breast cancer.